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Survivin belongs to the inhibitor of apoptosis (IAP)
protein family, and, in addition to the antiapoptotic
functions, it also regulates the cell cycle. The survivin
gene generates five major isoforms with diverse and
opposite functions. Survivin is highly expressed in
cancer and in few normal adult tissues, including skin.
It is mostly detected in the nucleus of keratinocyte
stem cells (KSCs), but it is also expressed in
melanocytes and fibroblasts. Survivin isoforms are
differentially detected in subpopulations of human
keratinocytes, exerting contrasting activities. Survivin
has an important role in the regulation of cell cycle in
keratinocytes, and it protects these cells from anoikis
and UV-induced apoptosis. In melanoma, survivin is
abundantly expressed, and its subcellular localization
varies depending upon tumor thickness and invasive-
ness. Survivin overexpression has been shown in
squamous cell carcinoma (SCC), and it is also involved
in UVB-induced carcinogenesis. The presence of
survivin both in the nucleus and in the cytoplasm
throughout the epidermal layers of psoriatic lesions
suggests the involvement of this protein in the
keratinocyte alterations typical of this disease. Addi-
tional studies on the expression of survivin isoforms
and their subcellular localization in relation to func-
tion will confirm the key role of survivin in the skin
and will open the field to new therapeutic strategies
for many cutaneous conditions.
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INTRODUCTION
The skin is the first protective barrier against any external
insult. To maintain this function, the epidermis is continu-
ously renewed. The regeneration process is ensured by the
presence of a stem cell reservoir located in the basal layer of
the epidermis. Keratinocyte stem cells (KSCs) have been
shown to have a highest capacity for self-renewal, quies-
cence, long persistence in the tissue, and resistance to
apoptosis (Pincelli and Marconi, 2010). KSCs generate transit-
amplifying (TA) cells that in turn, after a few rounds of
division, terminally differentiate into post-mitotic cells. The
progressive differentiation process leads to the formation of a
stratified epithelium composed of the basal layer, the spinous
layer, the granular layer, and the stratum corneum. The
presence and function of KSCs are essential for epidermal
homeostasis, which is characterized by a fine balance
between proliferation and differentiation/apoptosis of kerati-
nocytes. It should be pointed out that, in the skin, apoptosis
and differentiation are two separate mechanisms, in that they
appear to be independently activated in response to different
stimuli and involve distinct genes (Gandarillas et al., 1999).
Apoptosis is an evolutionary conserved process of auto-
destruction that is initiated by cells in response to different
stimuli, including UV radiation, toxins, hormones, and
cytokines (Kiess and Gallaher, 1998). Apoptosis is activated
to eliminate cells carrying highly damaged DNA, whereas it
is inhibited to preserve important cell functions. Either
intracellular or extracellular factors control apoptosis, trigger-
ing the intrinsic and/or the extrinsic apoptotic pathway,
respectively. Among the extracellular activators of apoptosis
are various factors that function by binding to death receptors
located on the cell surface, such as Fas and tumor necrosis
factor receptors. On the other hand, intracellular signals
include stress-activated factors that control mitochondrial
activity. At the molecular level, proteolytic caspases are the
main effectors of apoptosis, and they are involved in both the
extrinsic and intrinsic pathways. The extrinsic pathway is
centered on the activity of caspase-8, whereas the intrinsic
pathway is mediated by caspase-9. Both pathways stimulate
the effector caspase-3, which in turn activates a caspase3-
specific DNAse, which eventually degrades cellular DNA.
Apoptotic machinery has a major role in both normal
conditions and diseased tissues, including skin (Lippens
et al., 2009). To maintain epidermal homeostasis, the
apoptotic process is finely regulated by a number of
antiapoptotic molecules, including Akt and NF-kB. Akt
phosphorylates the proapoptotic protein Bad, thus preventing
its binding and inhibition of B-cell lymphoma 2 (Bcl-2) and
Bcl-Xl (Datta et al., 1997). NF-kB induces the transcription of
antiapoptotic genes such as the Bcl-2 and IAP (inhibitor of
apoptosis) families (Shih et al., 2011). This review sum-
marizes the expression and function of the most important
IAP family member, survivin, in the skin, both under
homeostatic and diseased conditions.
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THE DUAL FUNCTION OF SURVIVIN
The IAP family comprises Bruce, ILP2, Livin, survivin, NAIP,
c-IAP1, c-IAP2, and XIAP (X-linked IAP), which are struc-
turally different and, besides their common antiapoptotic
activity, appear to perform diverse functions (Figure 1). The
ability of the IAP to inhibit apoptosis by binding to caspases
and blocking their activity is guaranteed by a special domain
named BIR (baculovirus IAP repeat), which is present in their
structure in at least one copy. Unlike other IAPs, survivin not
only inhibits apoptosis but also regulates cell division (Altieri,
2010). This dual action, which distinguishes survivin from the
other IAP family members, is ensured by its unique structure.
Survivin has only one copy of a modified BIR domain, which
is used for the homodimerization of the protein and for its
interaction with other chromosome passenger proteins.
Phosphorylation of threonine 48 in the BIR domain influences
the dual ability of survivin to inhibit apoptosis and regulate
cell division. In addition, mutation of threonine 48 in the BIR
domain alters the ability of survivin to bind borealin, a
chromosome passenger protein (Barrett et al., 2011). The
structure of survivin also differs from that of other IAPs at the
C-terminal domain that is substituted by a coiled-coil a-helix
domain, which in turn is responsible for its regulation of cell
division. As far as inhibition of apoptosis is concerned, few
works had initially shown a possible association of survivin
with effector caspases in a cell-free system (Shin et al., 2001).
Yet, it has been recently demonstrated that, under physiolog-
ical conditions, survivin is not able to inhibit apoptosis by
directly binding to caspases (Srinivasula and Ashwell, 2008).
Under apoptotic stimuli involving mitochondria, survivin
forms a complex with XIAP, thus increasing the stability of
XIAP and its inhibitory activity against caspases (Dohi et al.,
2004a, b). Moreover, the binding of survivin to mitochondrial
Smac/DIABLO, a proapoptotic factor, leads to a delayed
Smac/DIABLO release in the cytoplasm, which then results in
prolonged cell survival (Ceballos-Cancino et al., 2007).
Another partner that facilitates survivin-mediated inhibition
of apoptosis is HBXIP (hepatitis B X-interacting protein).
Survivin and HBXIP form a complex, which in turn binds to
pro-caspase-9, preventing the activation of mitochondrial
apoptosis (Marusawa et al., 2003). Although IAPs are
generally considered antiapoptotic proteins, the gene encod-
ing for survivin, named BIRC5, generates five major isoforms
of the transcript by alternative splicing: wild-type (WT)-
survivin, survivin-2B, survivin-DEx3, survivin-3B, and survi-
vin-2a (Figure 1). Survivin-2a and survivin-2B favor induction
of apoptosis, whereas WT-survivin, survivin-DEx3, and
survivin-3B appear to be cytoprotective (Mahotka et al.,
1999; Badran et al., 2004; Caldas et al., 2005a). Among
survivin isoforms, survivin-2a is an example of regulation of
survivin function, in that it physically binds to WT-survivin,
thus limiting its antiapoptotic activity (Caldas et al.,
2005a, b). Some of the isoforms are also involved in the
control of cell division (Knauer et al., 2007).
Survivin is the only member of IAP family that is able to
interact with the mitotic apparatus, by binding to micro-
tubules through its C-terminal domain, thus ensuring correct
cell division (Srinivasula and Ashwell, 2008). Moreover, by
recognizing and complexing with phosphorylated histone
H3, survivin associates with the chromosome passenger
proteins Aurora B, INCENP, and Borealin, and the neoformed
complex is recruited to the mitotic centromers, in order to
assist and ensure proper chromosomal segregation (Kelly
et al., 2010). In addition, survivin localizes at the centro-
somes of dividing cells where it binds to Cdk1, the activation
of which allows the cells to enter mitosis (O’Connor et al.,
2000).
It has been proposed that the dual role of survivin is
associated with different compartimentalization of the
protein in the cells. Nuclear, cytoplasmic, and mitochondrial
pools of survivin have been previously described (Fortugno
et al., 2002; Dohi et al., 2004a, b). Nuclear localization
seems to be linked to the capacity of survivin to regulate cell
division, whereas mitochondrial survivin is associated with
inhibition of apoptosis (Fortugno et al., 2002; Colnaghi et al.,
2006). Nuclear survivin facilitates cell cycle progression by
inducing exit of the cells from G1 checkpoint arrest and
subsequent entry into S phase, but it is not protective against
apoptosis (Temme et al., 2007; Connell et al., 2008a, b).
Localization of survivin in the mitochondria, which corre-
sponds to a greater stability of the protein, is associated with
oncogenic transformation, possibly increasing protection
from apoptosis in cancer cells. Mitochondrial survivin confers
resistance to apoptosis by inhibiting activation of effector
caspases (Dohi et al., 2004a, b). On the other hand,
cytoplasmic survivin, after exiting from mitochondria once
apoptosis is initiated, loses its cytoprotective ability. It is
proposed that cytoplasmic survivin is not able to protect the
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Figure 1. The inhibitor of apoptosis (IAP) family members and survivin
isoforms. The IAP family includes eight members: XIAP (X-linked IAP),
c-IAP1, c-IAP2, ILP2 (IAP-like protein-2), ML-IAP (melanoma IAP)/Livin, NAIP
(neuronal apoptosis-inhibitory protein), and survivin. These proteins exert
antiapoptotic functions with the exception of survivin, which also regulates
the cell cycle. Alternative splicing of survivin transcript generates five major
isoforms characterized by different functions. BIR, baculovirus inhibitor of
apoptosis repeat; CARD, caspase recruitment domain; RING, really
interesting new gene; 30UTR, 30 untranslated region; WT, wild-type.
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cells from apoptosis because of posttranslational modifica-
tions (Dohi and Altieri, 2005). Mutations in survivin nuclear
export signal, which is responsible for its localization in the
cyctoplasm, results in the loss of protection against apoptosis
(Colnaghi et al., 2006). An extracellular pool of survivin has
been recently detected, retaining both antiapoptotic and
proliferative activities (Bokarewa et al., 2005; Mera et al.,
2008; Khan et al., 2009). Survivin release in the extracellular
space is mediated by exosomes and is induced by stress
stimuli (Khan et al., 2011). In addition, extracellular survivin
seems to have an important role in the pathogenesis of
rheumatoid arthritis (Ahn et al., 2010), suggesting that this
pool should also be explored in skin diseases. Although
survivin has been predominantly investigated in cancer, little
is known about its expression and function in normal adult
tissues such as skin.
SURVIVIN IN HEALTHY SKIN
Over the past 15 years, survivin has been an exciting field of
research, mainly because of its highest expression in human
cancers. Overall, survivin is poorly, or not, expressed in
normal adult tissues, whereas its expression markedly
increases in tumor cells, pointing to survivin as a putative
‘‘tumor-specific antigen.’’ In the skin, survivin expression
varies depending on the species analyzed. In rats, survivin is
expressed in both fetal skin and adult epidermis (Iskandar and
Al-Joudi, 2006), whereas adult mice do not express survivin
(Grossman et al., 2001). In human skin, survivin function has
long remained unclear because of several works showing the
absence of survivin in human adult epidermis (Grossman
et al., 1999). However, more recent reports have shown that
survivin is indeed expressed in normal human skin, and it is
localized in the cytoplasm of a few cells located in the basal
layer of the epidermis (Botchkareva et al., 2007; Marconi
et al., 2007). To identify the subpopulation of epidermal cells
expressing survivin, we isolated a population enriched in
KSCs (Jones and Watt, 1993; Marconi et al., 2007). Survivin
expression was mostly confined to KSCs in culture, with an
almost exclusively nuclear localization (Marconi et al.,
2007). This is in line with the concept of nuclear survivin
as the main pool that controls cell division (Fortugno et al.,
2002) and with recent findings showing survivin colocaliza-
tion with stem cell markers in other systems (Gheisari et al.,
2009; Li et al., 2010). The capacity of survivin to clearly
distinguish KSCs from TA keratinocytes is quite unique.
Indeed, other markers such as b1 integrin and p63 have been
shown to be expressed at higher levels in KSCs, although still
present in TA keratinocytes. In contrast, survivin behaves as
an almost exclusive marker for KSCs, and its expression is
almost absent in TA and post-mitotic cells (Marconi et al.,
2007).
Survivin isoforms are detected in different tissues and
appear to perform diverse functions. We have shown that all
the isoforms are expressed in human keratinocytes. In
particular, WT-survivin, survivin-2B, and survivin-DEx3 are
markedly expressed in KSCs, whereas survivin-3B and 2a are
downregulated in these cells and are mainly expressed in TA
and post-mitotic cells. On the basis of the expression pattern,
different roles could be hypothesized for survivin isoforms in
human epidermis: in particular, survivin-2B and survivin-
DEx3 could exert antiapoptotic functions, whereas survivin-
3B and survivin-2a may function as proapoptotic molecules
in this system (Marconi et al., 2007). Functional studies will
clarify the role of these isoforms in the skin.
Survivin is expressed more in human hair follicles than in
interfollicular epidermis. In the hair follicle, survivin is
expressed in ki67-positive keratinocytes located in the hair
matrix and outer root sheath, and it seems to both protect the
cells and regulate cell division (Botchkareva et al., 2007).
Whether survivin is expressed in the stem cell pool located in
the outer root sheath of the hair follicle remains to be
investigated.
As previously mentioned, survivin is involved in both
protection from apoptosis and cell cycle regulation. In human
keratinocytes, although survivin overexpression does not
induce changes in keratinocyte proliferation or differentia-
tion, survivin downregulation impairs the ability of these cells
to proliferate and form colonies in vitro (Grossman et al.,
2001; Dallaglio et al., 2009). These data suggest that survivin
is fundamental to sustain cell cycle progression and
proliferative potential in human keratinocytes. Moreover,
survivin is markedly upregulated during UVB-induced
keratinocyte cell cycle arrest, and its inhibition sensitizes
these cells to low doses of UVB, resulting in apoptosis
(Dallaglio et al., 2009).
KSCs are protected from apoptotic stimuli, such as
detachment from extracellular matrix (anoikis; Tiberio
et al., 2002) and UV radiation (Dallaglio et al., 2009). When
KSCs undergo anoikis, survivin-3B and survivin-2a are
upregulated, whereas WT-survivin, survivin-2B, and survi-
vin-DEx3 are downregulated. This suggests a possible role of
survivin isoforms in keratinocyte anoikis (Marconi et al.,
2007). Moreover, survivin protects human keratinocytes
against UVB-induced apoptosis (Grossman et al., 2001;
Dallaglio et al., 2009). Although immediately after apoptotic
doses of UVB, survivin is markedly upregulated in human
keratinocytes (Aziz et al., 2004), its expression decreases
24–48 hours after irradiation (Dallaglio et al., 2009), as is also
shown upon UVA-induced apoptosis (He et al., 2004). This
suggests that elevated levels of survivin help to protect cells
from cell death (Dallaglio et al., 2009). Moreover, anti-
apoptotic stimuli such as tea polyphenols and resveratrol
prevent UVB damage by downregulating UVB-induced
survivin expression (Aziz et al., 2005), suggesting that
survivin is modulated when apoptosis is inhibited by external
factors. Together, these data provide evidence that survivin is
important for both cell cycle progression and resistance to
apoptosis of human keratinocytes. Overall, endogenous
survivin seems to have a critical role in skin homeostasis,
possibly by functioning as a major factor to maintain the stem
cell reservoir of interfollicular epidermis.
In human melanocytes, survivin expression and functions
are controversial. In some reports, melanocytes do not seem
to express survivin in either interfollicular epidermis (Liu
et al., 2006; Thomas et al., 2007) or human hair follicle
(Botchkareva et al., 2007). In contrast, we have recently
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detected survivin in normal melanocytes in culture (Figure
2a and b), and Raj et al. (2008) have reported that survivin
expression in melanocytes is cell cycle dependent and that it
is regulated by p53 and Rb . This latter finding could explain
the apparent discrepancy. Ectopic expression of survivin in
melanocytes protects these cells from apoptosis, without
affecting their proliferation (Thomas et al., 2007). Interest-
ingly, treatment with an antisurvivin peptide induced
vitiligo in a melanoma patient, suggesting that survivin
may have a role in this disease, by regulating melanocyte
survival and proliferation (Fujita et al., 2009). Although
survivin in fibroblasts has been given little attention, normal
human and mouse fibroblasts express survivin and are used
as a tool for validation of new survivin-based therapeutic
approaches (Blanc-Brude et al., 2003). Survivin is also
detected in skin endothelial cells. It is expressed in
capillaries of normal epithelium, whereas it is upregulated
in endothelial cells of granulation tissue (O’Connor et al.,
2000). Following skin injury, endothelial cells revascularize
the damaged area by upregulating survivin expression (Byun
et al., 2007). In addition, survivin sustains endothelial cell
survival and proliferation (Dell’Eva et al., 2007), and
protects these cells from apoptosis (O’Connor et al., 2000;
Kirkiles-Smith et al., 2004). Consistently, the survivin-DEx3
isoform is directly involved in angiogenesis (Caldas et al.,
2007). Finally, a cell-permeable survivin/survivin isoform
delivery system has been proposed as a possible strategy
to improve revascularization of skin graft transplants
(Shu et al., 2007). Given the critical role of survivin in
cancer, its role in angiogenesis is worth further elucida-
tion, as targeting survivin in endothelial cells may be a
potential strategy to inhibit tumor-associated vessel growth
(O’Connor et al., 2000).
SURVIVIN IN DISEASED SKIN
Survivin is overexpressed in the majority of human cancers,
including that of lung, colon, uterus, brain, and ovary, as
compared with the normal counterpart (Altieri, 2001).
Indeed, survivin appears to be an important prognostic
marker and/or a chemoresistance predictive factor in several
human tumors, in that its high expression levels in neoplastic
tissues often correlate with poor prognosis (Zaffaroni et al.,
2005; Su et al., 2010; Taubert et al., 2010; Xiaoyuan et al.,
2010). In particular, the nuclear pool of survivin, rather than
cytoplasmic survivin, can function as an independent
prognostic factor for the clinical outcome of some human
cancers and can correlate with tumor resistance to common
therapeutic approaches. However, this effect seems to be
tumor-type dependent, as nuclear survivin is reported to be
an unfavorable prognostic factor in only some tumors (Moon
and Tarnawski, 2003), whereas it seems to indicate a
favorable prognosis in other forms of cancers, such as breast
and gastric carcinomas (Okada et al., 2001; Kennedy et al.,
2003). This is in line with what happens in the regression of
cutaneous T-cell lymphoma, a disease characterized by
migration of mutant T lymphocytes to the skin. In this type
of cancer, nuclear survivin is predictive of systemic disease
being associated with tumor progression (Goteri et al., 2007).
Because the two main pools of survivin are apparently
independent in terms of mechanism of action and differen-
tially important for cancer development and recurrence, the
subcellular distribution of survivin is of clinical relevance
(O’Connor et al., 2000; Xia and Altieri, 2006). Consistently,
the recently discovered mitochondrial pool of survivin seems
to have an important role in cancer biology. Indeed,
mitochondrial survivin protects cancer cells from apoptosis
and promotes tumor formation (Dohi et al., 2004a, b).
Similarly, extracellular survivin has been shown to have an
intriguing role in cancer maintenance. Tumor cells are able to
release survivin in the extracellular space via exosomes (Khan
et al., 2011). Here, it is promptly captured by neighboring
cancer cells, influencing and enhancing their proliferation,
invasive capacity, and resistance to therapy (Mera et al.,
2008; Khan et al., 2009). Normal stromal cells do not absorb
extracellular survivin, suggesting a tumor-specific mechanism
of auto-control.
Cutaneous tumors include both nonmelanoma and mel-
anoma skin cancers. In both types of cancers, survivin is
overall upregulated compared with normal skin (Chiodino
et al., 1999; Lo Muzio et al., 2001; Bowen et al., 2004; Park
et al., 2004; Bongiovanni et al., 2009).
MELANOMA
Human melanoma is the form of skin cancer responsible for
the highest number of deaths per year, and it has an innate
capacity to metastasize and resist therapy. Survivin is
Control ET-1 TPA
Human melanocytes
ET-1
Survivin
TPA
- 16.5 kDa
- 45 kDaβ-Actin
Figure 2. Survivin expression in human melanocytes in culture. (a) Normal human melanocytes were cultured with either endothelin or TPA. Cells were
fixed in 4% PFA, immunostained at room temperature with antisurvivin antibody, and analyzed by confocal microscopy. (b) Lysates from normal human
melanocytes cultured with either endothelin or TPA were analyzed by immunoblotting for survivin expression. b-Actin was used as a loading control. Survivin is
expressed in human melanocytes cultured with either endothelin or TPA. ET-1, endothelin-1; PFA, paraformaldehyde; TPA, 12-O-tetradecanoylphorbol-
13-acetate. Bar¼ 25 mm.
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overexpressed in human melanoma cells as compared with
normal melanocytes (Grossman et al., 1999), and this seems
to be a promoting factor for both early-step melanoma
formation in vivo (Thomas et al., 2007) and the migratory
capacity of melanoma cells (McKenzie et al., 2010).
Although in melanocytes, endogenous p53 and Rb repress
survivin expression by directly functioning on survivin
promoter, during melanocyte transformation, both p53 and
Rb signaling are deregulated, thus leading to survivin
overexpression, associated with melanoma growth (Raj
et al., 2008). Consistently, survivin has been recently
identified as a metastasis-associated gene for melanoma
(Kabbarah et al., 2010). In this respect, survivin expression in
sentinel lymph nodes of melanoma patients significantly
correlates with a poor prognosis, unlike other antiapoptotic
genes, further indicating survivin as a good prognostic marker
for melanoma invasiveness (Gradilone et al., 2003). Survivin
expression is higher in thick melanomas than in thin primary
tumors (Kabbarah et al., 2010). Nuclear survivin is reported
to be predominant in primary melanoma, dermal, and
congenital nevi, whereas cytoplasmic survivin is mainly
expressed in metastatic melanomas (Vetter et al., 2005),
suggesting that different distribution of the protein in
melanoma cells may correlate with the aggressiveness of
the tumor. According to some studies, survivin seems to be
exclusively expressed in the nuclei of malignant melanoma
(Ding et al., 2006). In others, both cytoplasmic and nuclear
survivin are detected in melanoma, although only the nuclear
pool is significantly correlated with poor outcome of the
patients (Piras et al., 2007, 2008; Chen et al., 2009). It should
be noted that all benign melanocytic lesions seem to be more
homogeneous with regard to survivin expression, and the
protein is consistently detected in these lesions (Florell et al.,
2005). Although survivin is released in the extracellular
space, human melanoma patients do not have increased
survivin serum levels compared with control patients. On the
contrary, survivin levels markedly increase when the patients
undergo chemotherapeutic treatment (Tas et al., 2004).
Survivin promoter activity is higher in melanoma cells as
compared with other major organs, behaving as a tumor-
specific promoter. Therefore, the use of survivin promoter to
restrict transgene expression to melanoma cells is promising
(Lu et al., 2005). Indeed, survivin downregulation sensitizes
melanoma cells to apoptosis (Pennati et al., 2002; Chawla-
Sarkar et al., 2004; Liu et al., 2004; Li et al., 2006), and
survivin upregulation is responsible for resistance to therapy
(Qiu et al., 2005). Consistently, low levels of survivin
expression in human melanomas predict better patient
outcome (Takeuchi et al., 2005). Both immunological and
peptide vaccines targeting survivin have been used as
putative therapeutic approaches against melanoma. Regula-
tory T cells against survivin have been found in the blood of
patients with metastatic melanoma and not in healthy
individuals (Vence et al., 2007), supporting the notion that
antisurvivin vaccines may be a good approach against this
disease (Reker et al., 2004; Otto et al., 2005). Although in
mouse models, targeting survivin induced apoptosis in
melanoma cells (Grossman et al., 2001; Yan et al., 2006),
preliminary results in patients were not as promising. YM155,
a small inhibitor of survivin, did not induce a positive
response in patients with stage III and IV melanomas (Lewis
et al., 2011). On the other hand, better results have been
obtained with therapeutic approaches based on survivin-
targeting immune therapy. Indeed, T cells against survivin
can persist in melanoma patients after complete remission of
the disease (Hadrup et al., 2006). A case report shows that
when patients with stage IV melanomas were vaccinated with
a survivin-derived epitope presented by dendritic cells, T-cell
response against survivin was high and reached melanoma
metastasis (Andersen et al., 2001; Otto et al., 2005). It is also
reported that some melanoma therapies can modulate
survivin expression, finally causing cell death (Pennati
et al., 2003; You et al., 2004).
NONMELANOMA SKIN CANCERS
Nonmelanoma skin cancers include SCC, basal cell carcino-
ma, and other less frequent tumors. Survivin is overexpressed
in human and mouse SCCs as compared with normal skin
(Bowen et al., 2004; Bongiovanni et al., 2009), and correlates
with tumor aggressiveness and lymph node metastasis (Lo
Muzio et al., 2001). This is also observed in head and neck
SCCs, where survivin overexpression correlates with tumor
progression and resistance to therapy. Survivin is expressed
both in benign precancerous lesions, such as actinic
keratosis, and in the actual SCC (Park et al., 2004), although
in tumor lesions its expression is more pronounced. In
contrast, human basal cell carcinomas weakly express
survivin (Chiodino et al., 1999; Bowen et al., 2004; Park
et al., 2004), suggesting the presence of a tumor-specific
expression pattern of survivin in the skin. In sebaceous
neoplasms, such as adenomas and carcinomas, only nuclear
survivin is expressed, and it increases in aggressive tumors
(Calder et al., 2008). In line with these findings, nuclear
survivin seems to be the predominant form, being expressed
in virtually 100% of human cutaneous SCC lesions, whereas
cytoplasmic survivin is present in less than one-third of the
cases (Bongiovanni et al., 2009).
In cutaneous SCC carcinogenesis, survivin seems to have a
crucial role. UVB, as one of the major causes of mutations in
the skin, favors the survival of p53-mutated clones, whereas it
induces apoptosis of normal cells. The proliferative advan-
tage of mutated cells allows the colonization of the
surrounding space leading to amplification of p53-mutated
cells. When survivin is overexpressed in keratinocytes, no
changes in cell differentiation and proliferation are observed.
On the other hand, survivin expression further suppresses
apoptosis, increasing the number of neo-formed p53-mutated
clones following UVB irradiation (Zhang et al., 2005).
Interestingly, expansion of p53-mutated clones is impaired
by survivin overexpression in mouse keratinocytes. This is in
line with the reduced susceptibility to form papillomas of
K14-survivin transgenic mice (Allen et al., 2003; Zhang et al.,
2005). These data suggest that the antiapoptotic function of
survivin favors the formation of mutated clones, yet inhibiting
their expansion. However, once the tumor is formed, survivin
is able to convert benign lesions to invasive SCCs (Allen
22 Journal of Investigative Dermatology (2012), Volume 132
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et al., 2003), thus having a key role in the progression of the
disease.
In tumor cells, survivin is highly expressed, sustains
proliferation, and protects from apoptosis. Common cancer
treatments induce apoptosis by downregulating survivin
expression (Roy et al., 2009). In line with this finding,
resveratrol, a grape-derivative protective factor against tumor
formation, reduces survivin upregulation following UVB-
induced carcinogenesis (Aziz et al., 2005). It remains to be
determined whether survivin also changes its intracellular
localization during apoptosis in cancer cells. We have
preliminary data showing that in cutaneous SCCs, survivin
shifts from the nucleus to the cytoplasm after treatment with
imiquimod (Figure 3a–e). Survivin expression and function
being tightly correlated is of paramount importance to
elucidate the subcellular localization of survivin before and
after treatment of cutaneous lesions.
MERKEL CELL CARCINOMA
Merkel cells are the mechanoreceptors of the skin and can
give rise to Merkel cell carcinoma, a rare and highly
aggressive malignant tumor with a high incidence of
recurrence. Both nuclear and cytoplasmic survivin are
expressed in all Merkel cell carcinomas, with higher
expression correlating with tumor recurrence and metastasis
(Tucci et al., 2006; Kim and McNiff, 2008). In the nucleus,
survivin colocalizes with the mitotic spindle markers,
suggesting a key role in the control of carcinoma cell
proliferation (Kim and McNiff, 2008). Cytoplasmic survivin is
detected in areas of Merkel cell carcinomas characterized by
large cell foci, predicting for better outcome. On the other
hand, nuclear survivin is associated with poor prognosis of
Merkel cell carcinoma, further confirming that studying the
intracellular distribution of survivin may predict tumor
aggressiveness (Kim and McNiff, 2008).
Before imiquimod treatment After imiquimod treatment
Figure 3. Survivin shifts from the nucleus to the cytoplasm of human cutaneous squamous cell carcinoma (SCC) cells after treatment with imiquimod.
(a–e) Immunohistochemical staining for survivin of (a) normal human skin, (b, c) Bowen’s disease, and (d, e) cutaneous SCC, (b, d) before and (c, e) after
treatment with imiquimod. (a) Cytoplasmic survivin is expressed in few basal keratinocytes of normal human epidermis; inset shows magnified view of the area
in the panel. (b, d) Survivin is expressed in Bowen’s disease and cutaneous SCC in suprabasal keratinocytes, at the nuclear level; inset shows magnified view
of the area in b and d. (c, e) Treatment with imiquimod, a therapy for skin cancer, reverts the histological phenotype from suprabasal to basal keratinocytes
and from nuclear to cytoplasmic localization, as seen in normal skin, after 8 weeks; inset shows magnified view of the area in c and e. Bar¼70 mm.
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PSORIASIS
Psoriasis is an immune-mediated skin condition character-
ized by hyperproliferation and reduced apoptosis of kerati-
nocytes. Survivin is expressed in 70–80% of psoriatic lesions,
and it is overexpressed in lesional skin as compared with
normal and uninvolved epidermis (Bowen et al., 2004;
Abdou and Hanout, 2008). In some studies, survivin is only
expressed in the cytoplasm of psoriatic keratinocytes (Mark-
ham et al., 2006), whereas in others both nuclear and
cytoplasmic survivin are observed. The cytoplasmic pool
seems to be the most frequent source of survivin in psoriatic
epidermis (Simonetti et al., 2009). Perinuclear survivin in
lesional psoriatic epidermis is also reported, but it does not
appear to correlate with either proliferative or apoptotic
activity (Bowen et al., 2004). Although in normal human skin
survivin is located only in few cells of the basal layer, in
psoriasis survivin is also expressed in the upper layers. In
particular, nuclear survivin is expressed in suprabasal layers
of psoriatic epidermis, whereas cytoplasmic survivin is
localized in both the basal and upper layers (Markham
et al., 2006; Simonetti et al., 2009). Because survivin protects
against apoptosis and regulates the cell cycle, it is con-
ceivable that it has an important role in the pathogenesis of
psoriasis. Survivin upregulation has been observed in the
epidermis of psoriatic patients treated with narrow-band UVB
combined with etanercept, a tumor necrosis factor-a in-
hibitor, suggesting a survivin-dependent increased risk of skin
cancer formation in psoriatic patients undergoing this kind of
combined therapy (Gambichler et al., 2011).
CONCLUSIONS AND FUTURE DIRECTIONS
We conclude that survivin is consistently expressed in several
skin cells and appears to function as a survival factor and as
an important cell cycle regulator. Most importantly, survivin
identifies KSCs (Marconi et al., 2007) and can be used as a
strong marker to characterize and isolate these cells.
Furthermore, given survivin expression and functions, it is
likely that survivin is involved in the mechanisms of
hyperproliferative skin diseases, such as cancer and psoriasis.
Subcellular localization of survivin is indicative of disease
progression and response to therapy. Indeed, nuclear survivin
is often associated with poor outcome in patients with skin
cancer, particularly with neoplasm recurrence. Thus, defining
cellular and subcellular expression in the tumor tissue is of
paramount importance. Moreover, clinical data associated
with survivin distribution in diseased versus normal skin,
before and after treatment, could help in clarifying the role of
survivin in the evaluation of the prognosis of patients and the
likelihood of disease recurrence. Targeting survivin in its
different cellular and subcellular locations will also provide a
strong therapeutic strategy (Moon and Tarnawski, 2003). In
addition, it would be very interesting to better explore the
role of the newly discovered survivin extracellular pool
(Figure 4) in normal and diseased skin conditions. Survivin
isoforms are very important in regulating survivin activity.
Some of these proteins interact with WT survivin, either
enhancing or inhibiting survivin-mediated protection from
apoptosis. To date, little is known about the role of survivin
splicing variants in the skin. We showed that all survivin
isoforms are expressed in normal human keratinocytes, the
antiapoptotic variants being more expressed in the stem cell
pool of the epidermis, probably cooperating in protecting
against apoptosis. Moreover, survivin isoforms are modulated
following keratinocyte apoptosis, suggesting a potential role
in the maintenance of epidermal homeostasis (Marconi et al.,
2007). It will be critical in the near future to better explore the
expression and function of survivin isoforms in normal and
diseased skin. Although different experimental strategies
targeting survivin have been developed in the past few years,
more studies are now needed at the skin level to develop new
treatments for inflammatory and neoplastic skin diseases.
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